A detailed history of Alliancebernstein L.P. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 2,017,088 shares of AKRO stock, worth $57.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,017,088
Previous 1,907,857 5.73%
Holding current value
$57.2 Million
Previous $44.8 Million 29.3%
% of portfolio
0.02%
Previous 0.02%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $2.34 Million - $3.2 Million
109,231 Added 5.73%
2,017,088 $57.9 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $5.25 Million - $7.06 Million
286,595 Added 17.68%
1,907,857 $44.8 Million
Q1 2024

May 14, 2024

BUY
$17.76 - $31.18 $241,020 - $423,143
13,571 Added 0.84%
1,621,262 $41 Million
Q4 2023

Feb 14, 2024

BUY
$11.38 - $50.33 $3.71 Million - $16.4 Million
325,981 Added 25.43%
1,607,691 $37.5 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $47.8 Million - $60.7 Million
1,161,305 Added 964.5%
1,281,710 $64.8 Million
Q2 2023

Aug 15, 2023

BUY
$36.89 - $56.88 $1.72 Million - $2.65 Million
46,515 Added 62.95%
120,405 $5.62 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $1.47 Million - $1.97 Million
39,310 Added 113.68%
73,890 $2.83 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $336,138 - $550,849
10,052 Added 40.98%
34,580 $1.89 Million
Q3 2022

Nov 15, 2022

BUY
$10.15 - $34.05 $31,749 - $106,508
3,128 Added 14.62%
24,528 $835,000
Q2 2022

Aug 15, 2022

BUY
$8.0 - $15.01 $43,200 - $81,054
5,400 Added 33.75%
21,400 $202,000
Q3 2021

Nov 10, 2021

SELL
$18.65 - $25.46 $54,084 - $73,834
-2,900 Reduced 15.34%
16,000 $358,000
Q2 2021

Jul 30, 2021

BUY
$24.81 - $32.35 $104,202 - $135,870
4,200 Added 28.57%
18,900 $469,000
Q1 2021

May 06, 2021

SELL
$24.04 - $34.19 $55,292 - $78,637
-2,300 Reduced 13.53%
14,700 $426,000
Q4 2020

Feb 08, 2021

SELL
$25.12 - $29.89 $42,704 - $50,813
-1,700 Reduced 9.09%
17,000 $439,000
Q3 2020

Nov 12, 2020

SELL
$30.79 - $39.92 $104,686 - $135,728
-3,400 Reduced 15.38%
18,700 $576,000
Q2 2020

Aug 13, 2020

BUY
$19.25 - $26.76 $152,075 - $211,404
7,900 Added 55.63%
22,100 $551,000
Q1 2020

May 14, 2020

BUY
$12.8 - $27.05 $181,760 - $384,110
14,200 New
14,200 $301,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.32B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.